Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OTX-DED for Short-Term Treatment of Dry Eye Disease
NCT04747977Phase 2Completed
- Sponsor
- Ocular Therapeutix
- Start
- Feb 2021
- Primary completion
- Aug 2021
- Modality
- Hydrogel Systems, Small Molecules, Device-based Delivery
- Countries
- 1
01
Overview
A Phase 2 trial of OTX-DED in dry eye disease (DED), sponsored by Ocular Therapeutix. Started Feb 2021; status: completed.
02
Drugs
OTX-DED
03
Conditions
dry eye disease (DED)
Beyond the preview
Go deeper on NCT04747977.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04747977.